Advertisement

DNP - Der Neurologe & Psychiater

, Volume 20, Issue 6, pp 74–84 | Cite as

Zwischen Manie und Depression

Fortschritte in der Diagnostik und Behandlung bipolarer Störungen

  • Heinz GrunzeEmail author
  • Schwäbisch Hall
Zertifizierte Fortbildung
  • 108 Downloads

Zusammenfassung

In den letzten 20 Jahren sind deutliche Fortschritte beim Verständnis der den bipolaren Störungen zugrunde liegenden genetischen und epigenetischen Mechanismen erzielt worden. Das neue Klassifikationssystem DSM 5 bietet mehr Flexibilität bei der Diagnostik und mit Einführung verschiedener Antipsychotika haben sich die Behandlungsmöglichkeiten in der Breite, nicht aber in der Spitze, verbessert. Die Evidenz für Psychotherapieverfahren bei bipolaren Störungen ist in den letzten zwei Dekaden ebenfalls deutlich angewachsen. Nicht zuletzt sind die Erfolge durch Einbindung von bipolar Erfahrenen als Genesungsbegleiter zu betonen.

Literatur

  1. 1.
    American Psychiatric Association: Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen, Bern, Toronto, Seattle, Hogrefe, 1996.Google Scholar
  2. 2.
    American Psychiatric Association: Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. ed 2., korrigierte Deutsche Auflage, Göttingen, Hogrefe, 2018.Google Scholar
  3. 3.
    Akiskal HS: The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996;16:4–14.CrossRefGoogle Scholar
  4. 4.
    Vieta E, Grunze H, Azorin JM et al: Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. J Affect Disord 2014;156:206–213.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    World Health Organization: ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS) 2018 version; 2019.Google Scholar
  6. 6.
    Parker G, Hadzi-Pavlovic D, Tully L: Distinguishing bipolar and unipolar disorders: an isomer model. J Affect Disord 2006;96:67–73CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Berk M, Post R, Ratheesh A et al: Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry 2017;16:236–244.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    van der Markt A, Klumpers UM, Draisma S et al: Testing a clinical staging model for bipolar disorder using longitudinal life chart data. Bipolar Disord 2019;21:228–234.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gershon ES, Bunney WE, Jr., Leckman JF et al: The inheritance of affective disorders: a review of data and of hypotheses. Behav Genet 1976;6:227–261.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Egeland JA: A genetic study of manic-depressive disorder among the old order Amish of Pennsylvania. Pharmacopsychiatry 1988;21:74–75.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ginns EI, Ott J, Egeland JA et al: A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish. Nat Genet 1996;12:431–435.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nöthen MM, Rietschel M, Propping P: Genetik der bipolar affektiven Erkrankung. medgen 1998;10:394–397.Google Scholar
  13. 13.
    Nöthen MM, Degenhardt F, Forstner AJ: Durchbrüche im Verständnis der molekularen Ursachen psychiatrischer Störungen. Nervenarzt 2019;90:99–106.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kato T: Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond. Schizophr Res 2017;187:62–66.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Morris G, Walder K, McGee SL et al: A model of the mitochondrial basis of bipolar disorder. Neurosci Biobehav Rev 2017;74:1–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Walden J, Grunze H, Olbrich H et al: Bedeutung von Kalziumionen und Kalziumantagonisten bei affektiven Psychosen. Fortschr Neurol Psychiatr 1992;60:471–476.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fattal O, Link J, Quinn K et al: Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007;12:429–438.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Corena-McLeod M, Walss-Bass C, Oliveros A et al: New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations. PLoS One 2013;8:e52147.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Musci RJ, Augustinavicius JL, Volk H: Gene-Environment Interactions in Psychiatry: Recent Evidence and Clinical Implications. Curr Psychiatry Rep 2019;21:81.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lichtenstein P, Yip BH, Bjork C et al: Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009;373:234–239.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509–522.CrossRefGoogle Scholar
  22. 22.
    Grunze H: Bipolar disorder; in Zigmond MJ, Rowland LP, Coyle JT, (eds): Neurobiology of Brain Disorders. London, Academic Press; 2015, pp 655–673.Google Scholar
  23. 23.
    Harrison PJ, Geddes JR, Tunbridge EM: The Emerging Neurobiology of Bipolar Disorder. Trends Neurosci 2018;41:18–30.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957–1966.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hastings RS, Parsey RV, Oquendo MA et al: Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology 2004;29:952–959.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Drevets WC, Price JL, Simpson JR, Jr. et al: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824–827CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Price JL, Drevets WC: Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 2012;16:61–71.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Salloway S, Cummings J: Subcortical disease and neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1994;6:93–99.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Baumann B, Bogerts B: Neuroanatomical studies on bipolar disorder. Br J Psychiatry 2001;178:142–147.CrossRefGoogle Scholar
  30. 30.
    Altshuler L, Bookheimer S, Proenza MA et al: Increased amygdala activation during mania: a functional magnetic resonance imaging study. Am J Psychiatry 2005;162:1211–1213.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Altshuler LL, Bookheimer SY, Townsend J et al: Blunted activation in orbitofrontal cortex during mania: a functional magnetic resonance imaging study. Biol Psychiatry 2005;58:763–769.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Chen CH, Suckling J, Lennox BR et al: A quantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord 2011;13:1–15.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Townsend J, Altshuler LL: Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord 2012;14:326–339.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Strakowski SM, Adler CM, Almeida J et al: The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord 2012;14:313–325.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Townsend J, Altshuler LL: Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord 2012;14:326–339.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Strakowski SM: Integration and consolidation - a neurophysiological model of bipolar disorder.; in Strakowski SM, (ed): The Bipolar Brain: Integrating Neuroimaging and Genetics. New York, Oxford University Press, 2012, pp 253–274.CrossRefGoogle Scholar
  37. 37.
    Fountoulakis KN, Yatham L, Grunze H et al: The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. Int J Neuropsychopharmacol 2017;20:121–179.PubMedGoogle Scholar
  38. 38.
    Schön S, Grunze H: Lamotrigin in der Behandlung von Patienten mit Bipolar-I und Bipolar-II-Störungen. Psychopharmakotherapie 2004;11:42–49.Google Scholar
  39. 39.
    Grunze H, Vieta E, Goodwin GM et al: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81–109.CrossRefGoogle Scholar
  40. 40.
    Pacchiarotti I, Bond DJ, Baldessarini RJ et al: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249–1262.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bond DJ, Noronha MM, Kauer-Sant’Anna M et al: Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry 2008;69:1589–1601.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Grunze H: Off-Label bei Manie und Depression? DNP 2016;17:31–37.CrossRefGoogle Scholar
  43. 43.
    Salcedo S, Gold AK, Sheikh S et al: Empirically supported psychosocial interventions for bipolar disorder: Current state of the research. J Affect Disord 2016;201:203–214.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hanssen I, van Dord MI, Compen FR et al: Exploring the clinical outcome of Mindfulness-Based Cognitive Therapy for bipolar and unipolar depressive patients in routine clinical practice: a pilot study. Int J Bipolar Disord 2019;7:18–0153.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Colom F, Vieta E, Martinez-Aran A et al: A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402–407.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Colom F, Vieta E, Sanchez-Moreno J et al: Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 2009;194:260–265.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Gippert SM, Switala C, Bewernick BH et al: Deep brain stimulation for bipolar disorder-review and outlook. CNS Spectr 2017;22:254–257.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Nierenberg AA, Alpert JE, Gardner-Schuster EE et al: Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008;64:455–460.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hasey G: Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy. Can J Psychiatry 2001;46:720–727.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Milev RV, Giacobbe P, Kennedy SH et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatry 2016;61:561–575.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Mahlke CI, Priebe S, Heumann K et al: Effectiveness of one-to-one peer support for patients with severe mental illness - a randomised controlled trial. Eur Psychiatry 2017;42:103–110.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gliddon E, Cosgrove V, Berk L et al: A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder. Bipolar Disord 2019;21:28–39.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Fletcher K, Foley F, Murray G: Web-Based Self-Management Programs for Bipolar Disorder: Insights From the Online, Recovery-Oriented Bipolar Individualised Tool Project. J Med Internet Res 2018;20:e11160.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bauer M, Grof P, Gyulai L et al: Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord 2004;6:67–74.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Schärer LO, Hartweg V, Valerius G et al: Life charts on a palmtop computer: first results of a feasibility study with an electronic diary for bipolar patients. Bipolar Disord 2002;4 Suppl 1:107–108.CrossRefGoogle Scholar
  56. 56.
    Kelly JF, Hoffman L, Vilsaint C et al: Peer support for mood disorder: Characteristics and benefits from attending the Depression and Bipolar Support Alliance mutual-help organization. J Affect Disord 2019;255:127–135.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Burckhardt CS, Anderson KL: The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes 2003;1:60. doi:  https://doi.org/10.1186/1477-7525-1-60.:60-61.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Rosa AR, Sanchez-Moreno J, Martinez-Aran A et al: Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health 2007;3:5.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Sylvia LG, Montana RE, Deckersbach T et al: Poor quality of life and functioning in bipolar disorder. Int J Bipolar Disord 2017;5:10–0078.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Bennett F, Hodgetts S, Altshuler L et al: Predictors of Psychosocial Outcome of Bipolar Disorder: Results from the Stanley Foundation Bipolar Network. Int J Bipolar Disord 2019. In press.Google Scholar
  61. 61.
    DGBS e.V.und DGPPN e.V.: S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0. http://www.leitlinie-bipolar.de/wp-content/uploads/2012/05/S3_Leitlinie-Bipolar_11052012_pdf.2012
  62. 62.
    Medici CR, Videbech P, Gustafsson LN et al: Mortality and secular trend in the incidence of bipolar disorder. J Affect Disord 2015;183:39–44.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Hou L, Heilbronner U, Degenhardt F et al: Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 2016;387:1085–1093.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Naughton M, Clarke G, O’Leary OF et al: A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 2014;156:24–35.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Berk M, Copolov DL, Dean O et al: N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468–475.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Fernandes BS, Gama CS, Cereser KM et al: Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45:995–1004.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Bocchio-Chiavetto L, Zanardini R, Bortolomasi M et al: Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 2006;16:620–624.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Shimizu E, Hashimoto K, Okamura N et al: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–75.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    de Oliveira GS, Cereser KM, Fernandes BS et al: Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009;43:1171–1174.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Goldstein BI, Kemp DE, Soczynska JK et al: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078–1090.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Goldsmith DR, Rapaport MH, Miller BJ: A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016;21:1696–1709.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Fernandes BS, Steiner J, Molendijk ML et al: C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 2016;3:1147–1156.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Dinan TG, Cryan JF: The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am 2017;46:77–89.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Pereira C, Chavarria V, Vian J et al: Mitochondrial Agents for Bipolar Disorder. Int J Neuropsychopharmacol 2018;21:550–569.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Evans SJ, Bassis CM, Hein R et al: The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res 2017;87:23–29.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Dickerson F, Severance E, Yolken R: The microbiome, immunity, and schizophrenia and bipolar disorder. Brain Behav Immun 2017;62:46–52.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Goldstein TR, Fersch-Podrat RK, Rivera M et al: Dialectical behavior therapy for adolescents with bipolar disorder: results from a pilot randomized trial. J Child Adolesc Psychopharmacol 2015;25:140–149.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Grunze H, Vieta E, Goodwin GM et al: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World J Biol Psychiatry 2009;10:85–116.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Grunze H, Vieta E, Goodwin GM et al: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14:154–219.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Psychiatrie Schwäbisch Hall & Paracelsus medizinische Privatuniversität Nürnberg, Klinik für Allgemeine Psychiatrie und Psychotherapie Ost, Klinikum am WeissenhofWeinsbergDeutschland
  2. 2.

Personalised recommendations